tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Precigen Inc

PGEN
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
4.150USD
+0.070+1.72%
์ข…๊ฐ€ย 05/13, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
1.45B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Precigen Inc ํšŒ์‚ฌ

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Companyโ€™s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Companyโ€™s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ PGEN
ํšŒ์‚ฌ ์ด๋ฆ„Precigen Inc
์ƒ์žฅ์ผAug 08, 2013
CEOSabzevari (Helen)
์ง์› ์ˆ˜143
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒAug 08
์ฃผ์†Œ20374 Seneca Meadows Parkway
๋„์‹œGERMANTOWN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ20876
์ „ํ™”13015569900
์›น์‚ฌ์ดํŠธhttps://precigen.com/
์ข…๋ชฉ ์ฝ”๋“œ PGEN
์ƒ์žฅ์ผAug 08, 2013
CEOSabzevari (Helen)

Precigen Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.64M
+8.83%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
202.10K
+45.27%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
107.14K
+39.30%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.64M
+8.83%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Apr 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Product
3.98M
41.05%
Service
3.89M
40.18%
Collaborationandlicensingagreements
1.82M
18.77%
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Product
3.98M
41.05%
Service
3.89M
40.18%
Collaborationandlicensingagreements
1.82M
18.77%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 9 hours ago
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 9 hours ago
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Third Security, LLC
32.62%
Merck Serono SA
5.79%
Patient Capital Management, LLC
5.24%
Point72 Asset Management, L.P.
5.13%
William H. Miller III Living Trust
4.88%
๊ธฐํƒ€
46.34%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Third Security, LLC
32.62%
Merck Serono SA
5.79%
Patient Capital Management, LLC
5.24%
Point72 Asset Management, L.P.
5.13%
William H. Miller III Living Trust
4.88%
๊ธฐํƒ€
46.34%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Venture Capital
33.48%
Investment Advisor
16.90%
Hedge Fund
10.17%
Investment Advisor/Hedge Fund
9.78%
Individual Investor
7.83%
Corporation
5.79%
Research Firm
2.08%
Bank and Trust
0.18%
Pension Fund
0.14%
๊ธฐํƒ€
13.66%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2026Q1
355
270.08M
75.82%
+16.22M
2025Q4
319
238.99M
67.55%
+20.23M
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Third Security, LLC
116.30M
32.86%
-7.65M
-6.17%
Mar 30, 2026
Merck Serono SA
20.65M
5.83%
--
--
Mar 31, 2025
Patient Capital Management, LLC
18.67M
5.28%
-7.79M
-29.43%
Dec 31, 2025
Point72 Asset Management, L.P.
18.29M
5.17%
+4.56M
+33.24%
Jan 22, 2026
William H. Miller III Living Trust
17.39M
4.91%
+17.39M
--
Jun 26, 2025
BlackRock Institutional Trust Company, N.A.
13.25M
3.74%
+2.51M
+23.41%
Dec 31, 2025
State Street Investment Management (US)
10.82M
3.06%
+6.34M
+141.10%
Dec 31, 2025
Tang Capital Management, LLC
5.62M
1.59%
-6.78M
-54.70%
Dec 31, 2025
Fidelity Management & Research Company LLC
4.65M
1.31%
+4.54M
+3887.74%
Dec 31, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
๋” ๋ณด๊ธฐ
Inspire Small/Mid Cap ESG ETF
๋น„์œจ0.24%
ProShares Ultra Nasdaq Biotechnology
๋น„์œจ0.14%
iShares Micro-Cap ETF
๋น„์œจ0.12%
Invesco Nasdaq Biotechnology ETF
๋น„์œจ0.12%
State Street SPDR S&P Biotech ETF
๋น„์œจ0.11%
Vanguard US Momentum Factor ETF
๋น„์œจ0.1%
Direxion Daily S&P Biotech Bull 3X Shares
๋น„์œจ0.06%
iShares Biotechnology ETF
๋น„์œจ0.05%
iShares Russell 2000 Growth ETF
๋น„์œจ0.03%
ProShares UltraPro Russell2000
๋น„์œจ0.02%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
KeyAI
๎™